Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford in collaboration with 25 teams across the world have published the largest study to date of the genetic basis of endometriosis.

Faces of two women, overlaid with illustration of dna

Their study included DNA from 60,600 women* with endometriosis and 701,900 controls. It revealed compelling evidence of a shared genetic basis for endometriosis and other types of pain seemingly unrelated to endometriosis, including migraine, back pain and multi-site pain. The study has also revealed that ovarian endometriosis has a different genetic basis from other disease manifestations. The results open up new avenues for designing new medical treatments targeting subtypes of endometriosis, or even the repurposing of existing pain treatments for endometriosis.

Endometriosis has enormous implications on the quality of a woman’s life. This severe inflammatory condition occurring in 5-10% of women of reproductive age (190 million globally) can cause constant and intense pelvic pain, fatigue, depression, anxiety, and infertility. It is characterized by the presence of tissue that resembles the uterus lining (endometrium) outside the uterus. The location of these endometriotic deposits is primarily on organs within the pelvis (e.g. ovaries, pelvic surfaces and ligaments, bowel or bladder), although more rarely it can also be found outside of the pelvis.  The huge impact on the health of many women is compounded by the fact that endometriosis can only reliably be diagnosed through surgery and sometimes imaging, and often takes many years to diagnose (8 years on average from first symptoms). Treatment is limited to repeated surgeries, and hormonal treatments with many side-effects that do not allow women to get pregnant.

We know that endometriosis can run in families, and therefore that genetic factors (heritability) play a role in how it develops in some women but not in others. So: are we deep wired to endure this pain? Very little is known about the causes of endometriosis, and studying genetics - by comparing the DNA code in women with and without the disease - can give us clues to the biological processes that are the basis for onset and progression.

Read the full story on the Nuffield Department of Women's and Reproductive Health. 

Notes

* Individuals with endometriosis included were born female. Endometriosis can affect women and those assigned female at birth, and in very rare instances those born male (https://www.endometriosis-uk.org).

 

Similar stories

RECOVERY trial team awarded MRC Impact Prize for Outstanding Team Impact

The Medical Research Council Prize Committee has awarded the RECOVERY trial team the MRC Impact Prize 2022 for Outstanding Team Impact.

Professor Sir Chris Whitty brings greater understanding of epidemics to Oxford

Chief Medical Officer of England Professor Sir Chris Whitty KCB FMedSci delivers the Sherrington Prize Lecture: Public Understanding of Science to an audience of Oxford staff and students.

Study shows delaying treatment for localised prostate cancer does not increase mortality risk

Active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery, reports the largest study of its kind.

Showcasing Oxford’s translational research for Rare Disease Day

Rare Disease Day is an annual awareness day that aims to educate and raise awareness for the 400 million people worldwide who live with a rare disease.

Prostate cancer AI diagnosis tool begins evaluation in Oxford

New artificial intelligence software that can help to spot prostate cancer is being trialled by researchers at Oxford University Hospitals (OUH) NHS Foundation Trust.

Unlocking the secrets of cAMP signalling in the heart: a pathway to targeted therapeutics

A new Department of Physiology, Anatomy and Genetics study has revealed key new insights into the role of cAMP signalling in both healthy and disease settings within the heart. Researchers have identified new cAMP nanodomains in cardiac muscle cells that have far reaching implications for the treatment of heart disease.